Laboratory Corp. of America (LH) Receives Daily Media Impact Rating of 0.18
Media coverage about Laboratory Corp. of America (NYSE:LH) has been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Laboratory Corp. of America earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 47.4243765985162 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s analysis:
- Rick Goldwasser – Benzinga (benzinga.com)
- Morgan Stanley: Quest Diagnostics Has Balanced Risk-Reward – Benzinga (benzinga.com)
- LabCorp’s Covance forms unit to focus on biologic drug development (finance.yahoo.com)
- 3 Top Healthcare Stocks to Buy in March (finance.yahoo.com)
- Laboratory Corp. of America Holdings (LH) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
Laboratory Corp. of America (NYSE LH) opened at $173.78 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.20 and a current ratio of 1.31. The firm has a market cap of $17,766.27, a P/E ratio of 18.16, a PEG ratio of 1.47 and a beta of 0.90. Laboratory Corp. of America has a 1-year low of $134.19 and a 1-year high of $181.71.
LH has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Laboratory Corp. of America from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Mizuho set a $178.00 target price on shares of Laboratory Corp. of America and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Barclays raised their price target on shares of Laboratory Corp. of America from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Monday, February 26th. They noted that the move was a valuation call. Jefferies Group set a $167.00 price target on shares of Laboratory Corp. of America and gave the stock a “hold” rating in a research report on Friday, November 24th. Finally, ValuEngine raised shares of Laboratory Corp. of America from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Laboratory Corp. of America presently has an average rating of “Buy” and a consensus price target of $188.33.
In other news, Director Adam H. Schechter sold 1,263 shares of Laboratory Corp. of America stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $169.29, for a total transaction of $213,813.27. Following the completion of the transaction, the director now directly owns 7,297 shares of the company’s stock, valued at approximately $1,235,309.13. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Glenn A. Eisenberg sold 8,400 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $167.36, for a total transaction of $1,405,824.00. Following the completion of the sale, the chief financial officer now directly owns 15,931 shares of the company’s stock, valued at approximately $2,666,212.16. The disclosure for this sale can be found here. 0.90% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “Laboratory Corp. of America (LH) Receives Daily Media Impact Rating of 0.18” was first published by Marea Informative and is the sole property of of Marea Informative. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.mareainformativa.com/2018/03/16/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-laboratory-corp-of-america-lh-stock-price-updated-updated-updated.html.
About Laboratory Corp. of America
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).
Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.